White paper addresses breast cancer diagnostic practices
CARPINTERIA, Calif.—Agilent Technologies Inc. recently published a white paper on the role of immunohistochemistry in diagnosing and treating breast cancer. The paper, “Breast Cancer Diagnosis: Past, Present and Future,” was made available at a recent gathering of the United States and Canadian Academy of Pathology. This paper is an overview of best practices and covers how clinically meaningful biomarkers and ancillary tests for breast cancer have been established, as well as the potential and shortcomings of using the biomarkers in diagnosis and treatment.
“By uniting morphological, immunohistochemical and molecular methods, pathologists can provide a comprehensive diagnosis that supports individualized therapy for breast cancer patients,” said Dr. Ping Tang, one of the co-authors from the University of Rochester. “By covering useful antibodies and molecular tests in one comprehensive source, we think this article will be a valuable educational resource for breast pathologists.”